Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their financials and risk profiles stack up?

Learn more about whether Recursion Pharmaceuticals, Inc. or Syndax Pharmaceuticals, Inc. is a better investment based on AAII ...

Demis says the web will change significantly into an agent-first web. AI agents won’t need human-style visual renders and ...

Your hard-earned money would be better spent elsewhere.

Google is expected to launch Gemini 3.5 Pro on July 17 with a rumored 2M-token context window and 'Deep Think' reasoning.

Google DeepMind is targeting July 17 for the general availability of Gemini 3.5 Pro — now four days away — but every specific claim circulating about the launch, including the date itself, the ...

These days, the frontier AI labs are all racing to build self-improving models. Some believe it’s the surest route to ...

As they scramble to keep their systems online, AI companies are making things expensive for the rest of us. Large language ...

I know I’m old because I remember when a B+ was a respectable grade. Now it’s more like an indictment. I’m a masochist if I ...

OpenAI’s expanding robotics and simulation efforts signal that embodied AI is becoming the next frontier, strengthening the ...

At the moment, many of the big AI systems used in drug discovery are closed-source, meaning they are proprietary and carry an ...

Rajeev Kejriwal’s Antheen occupies a special niche in the contemporary Hindi poetry precisely because of its quiet subtleness ...